Repatha

Small-cap biotech The Medicines Company (NASDAQ: MDCO) announced long-term results over the weekend from a midstage study of its lead product candidate Inclisiran, sending its shares higher. What Happened Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study...

Reviewing Amgen, Inc. (NASDAQ: AMGN)'s third-quarter results, Cowen said the results were boring but very safe. The firm maintains its Buy rating and $209 price target for the shares of the company. At the time of writing, shares of Amgen were trading down 1.67 percent at $174.54. Analysts...

Shares of Amgen, Inc. (NASDAQ: AMGN) fell 7 percent after the biotechnology company released data from its therapy called Repatha, which is used to lower the risk of heart attacks, strokes and heart problems. Amgen reported Repatha reduces the risk of heart attacks, stokes and other heart-related...

Esperion Therapeutics Inc (NASDAQ: ESPR) has maintained its upward momentum on Tuesday, surging higher by another 13.2 percent. While the massive 80 percent runup since January 30 was triggered by positive fundamental news, a major short squeeze may be fueling the stock's enduring momentum. On...

After the close on Monday, Amgen, Inc. (NASDAQ: AMGN) announced that the U.S. District Court of Delaware had denied the motion by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to stay the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (ADR) (NYSE: SNY) could come under pressure after a U.S. district court ruled in favor of Amgen, Inc. (NASDAQ: AMGN) in a patent infringement lawsuit. Lawsuit The U.S. District Court in Delaware's permanent injunction...

Amgen, Inc. (NASDAQ: AMGN) reported robust 2Q results on both the top and bottom lines, modestly beating expectations. Barclays’ Geoff Meacham maintained an Equal-Weight rating on the company, with a price target of $185. Further Acceleration Could Be Challenging “While we have fairly...

Following in the delay in the release of data by Amgen, Inc. (NASDAQ: AMGN) for its ongoing Repatha Phase 3 trials, Goldman Sachs’ Terence Flynn now believes that the Phase 3 IVUS data could be a more important near-term catalyst for the stock. Flynn maintains a Buy rating on the company,...

Amgen, Inc. (NASDAQ: AMGN) has won a patent suit against Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (ADR) (NYSE: SNY) over its cholesterol-lowering drug Repatha. Amgen said a Delaware jury ruled in favor of the company on the validity of two Amgen patents that describe...